---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001529"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T15:47:47.115229+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# USANA Q3 net sales $213M, EPS $0.59; narrows FY 2023 guidance

## Summary
- Q3 net sales $213M (-9% YoY); diluted EPS $0.59 (-24% YoY).
- Active customers 464,000 (-2% YoY); Asia Pacific region sales $170M (-7% YoY).
- Greater China net sales $107M (-3% YoY, +2% constant currency); active customers +8%.
- FY 2023 outlook narrowed: net sales $900-$920M, EPS $2.80-$3.05 (prev. $900-$950M, $2.65-$3.30).
- Repurchased 180K shares for $12M; ended quarter debt-free with $307M cash.

## SEC filing metadata
- accession: 0001157523-23-001529
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/0001157523-23-001529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/a53675959.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001529
- JSON: https://secwatch.observer/filing/0001157523-23-001529.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001529.txt

## Key facts
- Earnings Releases
  USANA HEALTH SCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $213 million, EPS $0.59.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $213 million
  - EPS: $0.59
  - Result: reported results
  source text: Third quarter net sales were $213 million versus $233 million during Q3 2022. Third quarter diluted EPS was $0.59 as compared with $0.78 during Q3 2022. Company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).
  evidence_url: https://www.sec.gov/Archives/edgar/data/896264/000115752323001529/0001157523-23-001529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.